Jazz Pharmaceuticals Plc Stock Cash And Equivalents

JAZZ Stock

USD 138.76 1.81 1.29%

Jazz Pharmaceuticals PLC fundamentals help investors to digest information that contributes to Jazz Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Jazz Stock. The fundamental analysis module provides a way to measure Jazz Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Jazz Pharmaceuticals stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Jazz Pharmaceuticals PLC Company Cash And Equivalents Analysis

Jazz Pharmaceuticals' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

Cash

Bank Deposits

+

Liquidities

More About Cash And Equivalents | All Equity Analysis

Current Jazz Pharmaceuticals Cash And Equivalents

899.36 M

Most of Jazz Pharmaceuticals' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Jazz Pharmaceuticals PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Jazz Cash And Equivalents Driver Correlations

Understanding the fundamental principles of building solid financial models for Jazz Pharmaceuticals is extremely important. It helps to project a fair market value of Jazz Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since Jazz Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Jazz Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Jazz Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Good Will	Short Term Investments	Total Liab	Total Current Assets	Intangible Assets	Property Plant Equipment	Current Deferred Revenue	Short Term Debt	Common Stock	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Long Term Debt Total	Short Long Term Debt	Net Invested Capital	Long Term Investments	Net Working Capital	Capital Stock
Total Assets		0.92	0.31	0.8	0.95	0.98	0.98	0.99	0.34	0.99	0.91	0.96	0.95	0.67	0.4	0.0	-0.9	0.91	0.7	0.97	-0.43	0.92	0.7	0.8	-0.53
Total Stockholder Equity	0.92		0.23	0.94	0.82	0.83	0.91	0.92	0.59	0.84	0.88	0.85	0.92	0.59	0.41	0.15	-0.68	0.89	0.57	0.81	-0.51	0.75	0.77	0.77	-0.47
Net Debt	0.31	0.23		0.15	0.46	0.28	0.24	0.36	-0.31	0.33	-0.04	0.52	0.28	-0.32	0.36	0.59	-0.43	0.43	-0.09	0.24	-0.05	0.34	0.17	-0.04	0.56
Retained Earnings	0.8	0.94	0.15		0.66	0.68	0.79	0.8	0.7	0.69	0.77	0.72	0.85	0.5	0.34	0.14	-0.51	0.79	0.49	0.66	-0.58	0.56	0.76	0.69	-0.42
Accounts Payable	0.95	0.82	0.46	0.66		0.95	0.94	0.95	0.14	0.96	0.81	0.95	0.92	0.61	0.45	0.05	-0.92	0.88	0.63	0.94	-0.29	0.93	0.68	0.7	-0.39
Long Term Debt	0.98	0.83	0.28	0.68	0.95		0.96	0.96	0.22	1.0	0.89	0.94	0.91	0.69	0.33	-0.12	-0.94	0.86	0.74	1.0	-0.4	0.94	0.63	0.78	-0.57
Net Receivables	0.98	0.91	0.24	0.79	0.94	0.96		0.97	0.39	0.97	0.95	0.9	0.94	0.74	0.46	-0.06	-0.85	0.9	0.76	0.96	-0.38	0.9	0.71	0.83	-0.57
Good Will	0.99	0.92	0.36	0.8	0.95	0.96	0.97		0.29	0.97	0.88	0.97	0.95	0.63	0.4	0.11	-0.9	0.92	0.71	0.95	-0.48	0.88	0.68	0.74	-0.48
Short Term Investments	0.34	0.59	-0.31	0.7	0.14	0.22	0.39	0.29		0.22	0.55	0.16	0.37	0.36	0.22	-0.14	0.06	0.35	0.19	0.23	-0.27	0.17	0.63	0.58	-0.42
Total Liab	0.99	0.84	0.33	0.69	0.96	1.0	0.97	0.97	0.22		0.88	0.96	0.92	0.68	0.38	-0.07	-0.95	0.88	0.73	0.99	-0.38	0.95	0.64	0.77	-0.53
Total Current Assets	0.91	0.88	-0.04	0.77	0.81	0.89	0.95	0.88	0.55	0.88		0.76	0.85	0.83	0.42	-0.21	-0.71	0.8	0.75	0.9	-0.33	0.84	0.68	0.89	-0.72
Intangible Assets	0.96	0.85	0.52	0.72	0.95	0.94	0.9	0.97	0.16	0.96	0.76		0.92	0.5	0.34	0.13	-0.94	0.89	0.6	0.92	-0.45	0.88	0.63	0.65	-0.35
Property Plant Equipment	0.95	0.92	0.28	0.85	0.92	0.91	0.94	0.95	0.37	0.92	0.85	0.92		0.63	0.31	-0.02	-0.83	0.88	0.62	0.91	-0.53	0.83	0.78	0.74	-0.51
Current Deferred Revenue	0.67	0.59	-0.32	0.5	0.61	0.69	0.74	0.63	0.36	0.68	0.83	0.5	0.63		0.46	-0.47	-0.59	0.5	0.8	0.74	-0.03	0.65	0.45	0.71	-0.79
Short Term Debt	0.4	0.41	0.36	0.34	0.45	0.33	0.46	0.4	0.22	0.38	0.42	0.34	0.31	0.46		0.17	-0.31	0.43	0.34	0.36	0.36	0.43	0.29	0.35	0.03
Common Stock	0.0	0.15	0.59	0.14	0.05	-0.12	-0.06	0.11	-0.14	-0.07	-0.21	0.13	-0.02	-0.47	0.17		0.05	0.18	-0.2	-0.18	-0.21	-0.16	-0.01	-0.28	0.6
Net Tangible Assets	-0.9	-0.68	-0.43	-0.51	-0.92	-0.94	-0.85	-0.9	0.06	-0.95	-0.71	-0.94	-0.83	-0.59	-0.31	0.05		-0.79	-0.7	-0.94	0.32	-0.9	-0.49	-0.6	0.4
Capital Surpluse	0.91	0.89	0.43	0.79	0.88	0.86	0.9	0.92	0.35	0.88	0.8	0.89	0.88	0.5	0.43	0.18	-0.79		0.57	0.84	-0.42	0.88	0.71	0.83	-0.23
Deferred Long Term Liab	0.7	0.57	-0.09	0.49	0.63	0.74	0.76	0.71	0.19	0.73	0.75	0.6	0.62	0.8	0.34	-0.2	-0.7	0.57		0.76	-0.28	0.62	0.39	0.58	-0.65
Long Term Debt Total	0.97	0.81	0.24	0.66	0.94	1.0	0.96	0.95	0.23	0.99	0.9	0.92	0.91	0.74	0.36	-0.18	-0.94	0.84	0.76		-0.35	0.95	0.62	0.79	-0.6
Short Long Term Debt	-0.43	-0.51	-0.05	-0.58	-0.29	-0.4	-0.38	-0.48	-0.27	-0.38	-0.33	-0.45	-0.53	-0.03	0.36	-0.21	0.32	-0.42	-0.28	-0.35		-0.17	-0.37	-0.23	0.26
Net Invested Capital	0.92	0.75	0.34	0.56	0.93	0.94	0.9	0.88	0.17	0.95	0.84	0.88	0.83	0.65	0.43	-0.16	-0.9	0.88	0.62	0.95	-0.17		0.59	0.84	-0.42
Long Term Investments	0.7	0.77	0.17	0.76	0.68	0.63	0.71	0.68	0.63	0.64	0.68	0.63	0.78	0.45	0.29	-0.01	-0.49	0.71	0.39	0.62	-0.37	0.59		0.66	-0.35
Net Working Capital	0.8	0.77	-0.04	0.69	0.7	0.78	0.83	0.74	0.58	0.77	0.89	0.65	0.74	0.71	0.35	-0.28	-0.6	0.83	0.58	0.79	-0.23	0.84	0.66		-0.52
Capital Stock	-0.53	-0.47	0.56	-0.42	-0.39	-0.57	-0.57	-0.48	-0.42	-0.53	-0.72	-0.35	-0.51	-0.79	0.03	0.6	0.4	-0.23	-0.65	-0.6	0.26	-0.42	-0.35	-0.52

Click cells to compare fundamentals

Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).

Competition

Predict Jazz Pharmaceuticals

Jazz Cash And Cash Equivalents Changes

Cash And Cash Equivalents Changes

279.96 Million

At this time, Jazz Pharmaceuticals' Cash And Cash Equivalents Changes is fairly stable compared to the past year.

In accordance with the recently published financial statements, Jazz Pharmaceuticals PLC has 899.36 M in Cash And Equivalents. This is 9.56% higher than that of the Pharmaceuticals sector and 101.15% higher than that of the Health Care industry. The cash and equivalents for all United States stocks is 66.72% higher than that of the company.

Jazz Cash And Equivalents Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Jazz Pharmaceuticals' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Jazz Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Jazz Pharmaceuticals by comparing valuation metrics of similar companies.

Jazz Pharmaceuticals is currently under evaluation in cash and equivalents category among its peers.

Jazz Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Jazz Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Jazz Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

Jazz Fundamentals

	Return On Equity	0.14
	Return On Asset	0.046
	Profit Margin	0.14 %
	Operating Margin	0.21 %
	Current Valuation	11.71 B
	Shares Outstanding	60.73 M
	Shares Owned By Insiders	3.08 %
	Shares Owned By Institutions	99.91 %
	Number Of Shares Shorted	4.53 M
	Price To Earning	35.18 X
	Price To Book	2.09 X
	Price To Sales	2.10 X
	Revenue	4.07 B
	Gross Profit	3.76 B
	EBITDA	716.63 M
	Net Income	560.12 M
	Cash And Equivalents	899.36 M
	Cash Per Share	14.28 X
	Total Debt	69.94 M
	Debt To Equity	2.12 %
	Current Ratio	3.16 X
	Book Value Per Share	67.52 X
	Cash Flow From Operations	1.4 B
	Short Ratio	4.96 X
	Earnings Per Share	8.53 X
	Price To Earnings To Growth	0.44 X
	Target Price	193.58
	Number Of Employees	2.8 K
	Beta	0.44
	Market Capitalization	8.54 B
	Total Asset	12.01 B
	Retained Earnings	1.13 B
	Working Capital	3.59 B
	Current Asset	1.26 B
	Current Liabilities	226.64 M
	Net Asset	12.01 B

About Jazz Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Jazz Pharmaceuticals PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Jazz Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Jazz Pharmaceuticals PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
S	SentinelOne
GM	General Motors

Additional Tools for Jazz Stock Analysis

When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC